Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Fig. 3

KM estimates of OS: patients with EGFR Mut + advanced NSCLC who ever received a TKI Kaplan-Meier estimates of overall survival of patients with EGFR Mut + advanced NSCLC who ever received either a TKI (a) or gefitinib (b) during their entire course of treatment compared with those who did not receive a TKI. KM, Kaplan-Meier; Mut+, mutation-positive; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us